Bryan C Batch1, Kristen Hyland, Laura P Svetkey. 1. aDepartment of Medicine, Division of Endocrinology, Metabolism and Nutrition bDepartment of Medicine, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
PURPOSE OF REVIEW: There is burgeoning evidence that branch chain amino acids (BCAAs) are biomarkers of metabolic, cardiovascular, renal and cerebrovascular disease. The purpose of this review is to summarize the current evidence in this area. RECENT FINDINGS: Recent evidence demonstrates that BCAAs are associated with insulin resistance, type 2 diabetes, risk of cardiovascular disease, stage I and II chronic kidney disease and ischemic stroke. Further, circulating levels of BCAAs have the potential to predict populations at risk for cardiometabolic disease, type 2 diabetes and mortality from ischemic heart disease. Importantly, the relationship of BCAAs to insulin resistance is affected by the intake of fat in the diet as well as age. SUMMARY: Current evidence supports the potential use of BCAAs as biomarkers of disease. However, questions regarding the mechanisms underlying the relationship of BCAAs to disease process and severity need to be answered prior to the use of BCAAs as a biomarker in clinical practice.
PURPOSE OF REVIEW: There is burgeoning evidence that branch chain amino acids (BCAAs) are biomarkers of metabolic, cardiovascular, renal and cerebrovascular disease. The purpose of this review is to summarize the current evidence in this area. RECENT FINDINGS: Recent evidence demonstrates that BCAAs are associated with insulin resistance, type 2 diabetes, risk of cardiovascular disease, stage I and II chronic kidney disease and ischemic stroke. Further, circulating levels of BCAAs have the potential to predict populations at risk for cardiometabolic disease, type 2 diabetes and mortality from ischemic heart disease. Importantly, the relationship of BCAAs to insulin resistance is affected by the intake of fat in the diet as well as age. SUMMARY: Current evidence supports the potential use of BCAAs as biomarkers of disease. However, questions regarding the mechanisms underlying the relationship of BCAAs to disease process and severity need to be answered prior to the use of BCAAs as a biomarker in clinical practice.
Authors: Ming Ding; Oana A Zeleznik; Marta Guasch-Ferre; Jie Hu; Jessica Lasky-Su; I-Min Lee; Rebecca D Jackson; Aladdin H Shadyab; Michael J LaMonte; Clary Clish; A Heather Eliassen; Frank Sacks; Walter C Willett; Frank B Hu; Kathryn M Rexrode; Peter Kraft Journal: Am J Epidemiol Date: 2019-11-01 Impact factor: 4.897
Authors: Qian Xiao; Steven C Moore; Sarah K Keadle; Yong-Bing Xiang; Wei Zheng; Tricia M Peters; Michael F Leitzmann; Bu-Tian Ji; Joshua N Sampson; Xiao-Ou Shu; Charles E Matthews Journal: Int J Epidemiol Date: 2016-04-12 Impact factor: 7.196
Authors: Qian Xiao; Andriy Derkach; Steven C Moore; Wei Zheng; Xiao-Ou Shu; Fangyi Gu; Neil E Caporaso; Joshua N Sampson; Charles E Matthews Journal: Metabolomics Date: 2017-04-06 Impact factor: 4.290
Authors: Clare Edwards; John Canfield; Neil Copes; Andres Brito; Muhammad Rehan; David Lipps; Jessica Brunquell; Sandy D Westerheide; Patrick C Bradshaw Journal: BMC Genet Date: 2015-02-03 Impact factor: 2.797
Authors: J B Delaye; D Lanznaster; C Veyrat-Durebex; A Fontaine; G Bacle; A Lefevre; R Hergesheimer; J C Lecron; P Vourc'h; C R Andres; F Maillot; P Corcia; P Emond; H Blasco Journal: Neurotherapeutics Date: 2020-10-06 Impact factor: 7.620